Jan 6, 2026, 13:39
JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
JAMA Neurology shared on LinkedIn:
”In patients with ischemic stroke and concurrent nonvalvular atrial fibrillation and ASCVD, adding an antiplatelet agent to anticoagulant therapy offered no net clinical benefit over anticoagulant monotherapy.
Read the full article in JAMA.
Article: Optimal Antithrombotics for Ischemic Stroke and Concurrent Atrial Fibrillation and Atherosclerosis. A Randomized Clinical Trial
Authors: Shuhei Okazaki, Kanta Tanaka, Yukako Yazawa et al.
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate
-
Sep 29, 2026, 22:42Nova Sinclair: Advancing the Future of Hematology – Meet Our 2027 Organizing Committee
-
Sep 29, 2026, 22:41Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
-
Sep 29, 2026, 22:31Selma Turkovic: Pleased to Deliver the Opening Presentation at Kingston Hospital
-
Sep 29, 2026, 22:31Miguel Teran: Ultrasound and Simulation in Arterial Blood Sampling
-
Sep 29, 2026, 22:28Mohammad Refaei: Navigating Your Career in Hematology From Training to Practice
-
Sep 29, 2026, 22:27Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention